MaxCyte Inc (NAS:MXCT)

Q3 2025 MaxCyte Inc Earnings Call Transcript

Nov 12, 2025 / 09:30 PM GMT

Release Date Price: $1.58 (+1.94%)

Transcript 10-Q8-K

Key Points

Positve

MaxCyte Inc (MXCT) reported $6.8 million in total revenue for Q3 2025, aligning with expectations despite a challenging operating environment.
The company signed a new strategic platform license with Moonlight Bio, bringing the total number of signed SPLs to four this year, consistent with their guidance.
MaxCyte Inc (MXCT) anticipates five of its current 18 clinical programs to enter pivotal studies in the next 6 to 18 months, with potential commercial launches in 2027 and 2028.
The company expects to realize $17 to $19 million in annualized savings from a restructuring initiative, which includes a 34% workforce reduction.
MaxCyte Inc (MXCT) maintains a strong cash position with $158 million in cash equivalents and investments, providing a solid financial foundation for future growth.

Negative

Total revenue for Q3 2025 decreased to $6.8 million from $8.2 million in Q3 2024, reflecting a challenging market environment.
Core revenue, including instrument, license, and processing assembly revenue, declined compared to the previous year due to customer program consolidations.
The company faced a challenging funding environment for XPO therapies, leading to slower-than-expected commercial adoption.
MaxCyte Inc (MXCT) had to engage in a restructuring initiative, including a significant workforce reduction, to align with the current market conditions.
The company anticipates continued impact from key customer program rationalizations, affecting growth through the first half of next year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MXCT.OQ - MaxCyte Inc
Q3 2025 MaxCyte Inc Earnings Call
Nov 12, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Mac site 3rd quarter earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you will need to press 11 on your telephone. You will then hear an automated message advising you your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Eric Abdow Investor relations. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.